These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28858250)

  • 1. Solution NMR Studies of Mycobacterium tuberculosis Proteins for Antibiotic Target Discovery.
    Kim DH; Kang SM; Lee BJ
    Molecules; 2017 Aug; 22(9):. PubMed ID: 28858250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
    Musa TL; Ioerger TR; Sacchettini JC
    Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
    Lou Z; Zhang X
    Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: insights from biochemical studies and crystal structures.
    Fonvielle M; Le Du MH; Lequin O; Lecoq A; Jacquet M; Thai R; Dubois S; Grach G; Gondry M; Belin P
    J Biol Chem; 2013 Jun; 288(24):17347-59. PubMed ID: 23620594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C.
    Scheich C; Puetter V; Schade M
    J Med Chem; 2010 Dec; 53(23):8362-7. PubMed ID: 21073150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phylogenetic and Structural Significance of Dihydrofolate Synthase (folC) Mutations in Drug-Resistant Mycobacterium tuberculosis.
    Cheng VW; Leung KS; Kwok JS; Leung RK; Yang KY; Chan RC; Kam KM; Tsui SK
    Microb Drug Resist; 2016 Oct; 22(7):545-551. PubMed ID: 27082669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.
    Kling A; Lukat P; Almeida DV; Bauer A; Fontaine E; Sordello S; Zaburannyi N; Herrmann J; Wenzel SC; König C; Ammerman NC; Barrio MB; Borchers K; Bordon-Pallier F; Brönstrup M; Courtemanche G; Gerlitz M; Geslin M; Hammann P; Heinz DW; Hoffmann H; Klieber S; Kohlmann M; Kurz M; Lair C; Matter H; Nuermberger E; Tyagi S; Fraisse L; Grosset JH; Lagrange S; Müller R
    Science; 2015 Jun; 348(6239):1106-12. PubMed ID: 26045430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.
    Gupta AK; Katoch VM; Chauhan DS; Sharma R; Singh M; Venkatesan K; Sharma VD
    Microb Drug Resist; 2010 Mar; 16(1):21-8. PubMed ID: 20001742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PhoP, a key player in Mycobacterium tuberculosis virulence.
    Ryndak M; Wang S; Smith I
    Trends Microbiol; 2008 Nov; 16(11):528-34. PubMed ID: 18835713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential impact of structural genomics on tuberculosis drug discovery.
    Arcus VL; Lott JS; Johnston JM; Baker EN
    Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural measurements and cell line studies of the copper-PEG-Rifampicin complex against Mycobacterium tuberculosis.
    Manning T; Mikula R; Wylie G; Phillips D; Jarvis J; Zhang F
    Bioorg Med Chem Lett; 2015 Feb; 25(3):451-8. PubMed ID: 25575660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in discovery of new drugs for tuberculosis therapy.
    Riccardi G; Pasca MR
    J Antibiot (Tokyo); 2014 Sep; 67(9):655-9. PubMed ID: 25095807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
    Sharma A; Jain K; Flora SJS
    Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.
    Fakhar Z; Naiker S; Alves CN; Govender T; Maguire GE; Lameira J; Lamichhane G; Kruger HG; Honarparvar B
    J Biomol Struct Dyn; 2016 Nov; 34(11):2399-417. PubMed ID: 26612108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery.
    Płocinska R; Korycka-Machala M; Plocinski P; Dziadek J
    Curr Top Med Chem; 2017 Jun; 17(19):2129-2142. PubMed ID: 28137234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
    Yew WW; Koh WJ
    Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.